Angion tanks as it ditches Phase II Trial of ANG-3070 in KD

Angion Biomedica (Nasdaq: ANGN) saw its shares close down 33% on Thursday and fall a further 6% to $1.07 pre-market today, after the US company announced it will discontinue the Phase II JUNIPER study of ANG-3070 in patients with primary proteinuric kidney diseases.

This trial, which began enrolling patients in December 2021, is being discontinued in the interest of patient safety based upon a reassessment of the risk/benefit profile of ANG-3070 in patients with established serious kidney disease, said Angion.

This reassessment was conducted following the occurrence of a potential safety signal of an unexpected and substantial decline in kidney function in a patient in the trial’s drug treatment arm and took into account a number of factors, including an evaluation of the totality of the data Angion has reviewed with respect to ANG-3070, known TKI class side effects, including potential adverse effects on the kidney, and an analysis of the blinded patient data which did not detect any early treatment signal indicating a reduction in proteinuria. These factors collectively lead Angion to believe discontinuation of the JUNIPER study is in the best interest of patients.